<DOC>
	<DOCNO>NCT01611116</DOCNO>
	<brief_summary>Standard chemotherapy capable eliminate leukemic blast acute myeloblastic leukemia ( AML ) , leukemia-initiating cell sufficiently eradicate . As consequence , refractory disease relapse frequently occur AML , especially elderly patient . The investigator propose addition temsirolimus may improve standard AML chemotherapy . Furthermore , temsirolimus may specifically target leukemia-initiating cell AML , thereby reduce risk leukemia relapse . The study 's main part precede open label run-in part , optimal temsirolimus dose schedule main part study determine .</brief_summary>
	<brief_title>Study With Temsirolimus Added Standard Chemotherapy Patients Over 60 Years With Acute Myeloblastic Leukemia</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<criteria>Newly diagnose AML ( except APL ) accord FAB classification , include AML evolve MDS hematological disease AML previous cytotoxic therapy radiation ( secondary AML ) Bone marrow aspirate biopsy contain ≥ 20 % blast nucleate cell differential blood count must contain ≥ 20 % blast . In AML FAB M6 ≥ 30 % nonerythroid cell bone marrow must leukemic blast . In AML define cytogenetic aberration proportion blast may &lt; 20 % . Age ≥ 61 year Informed consent , personally sign date participate study Willingness male patient whose sexual partner woman childbearing potential ( WOCBP ) , use effective form contraception ( pearl index &lt; 1 % ) study least 6 month thereafter . Patients eligible standard chemotherapy Previous treatment AML , except leukapheresis patient hyperleukocytosis ( leukocytes &gt; 100,000/µl / leukostatic syndrome ) hydroxyurea Known central nervous system manifestation AML Cardiac Disease : Heart failure NYHA III° IV° ; active coronary artery disease ( MI 6 month prior study entry permit ) ; serious cardiac ventricular arrhythmia , define : ventricular extrasystole grade LOWN IV , sustain nonsustained ventricular tachycardia , history ventricular fibrillation / ventricular flutter , unless patient protect internal cardioverter / defibrillator ventricular arrhythmia attributable myocardial ischemia &gt; 6 month study entry . Chronically impaired renal function ( creatinine clearance &lt; 30 ml / min ) Chronic pulmonary disease relevant hypoxia Inadequate liver function ( ALT AST ≥ 2.5 x ULN ) cause leukemic infiltration Total bilirubin ≥ 1.2 mg/dL cause leukemic infiltration Uncontrolled active infection Concurrent malignancy AML estimate life expectancy less two year require therapy Known HIV and/or hepatitis C infection Evidence history CNS disease , include primary metastatic brain tumor , seizure disorder History organ allograft Concomitant treatment kinase inhibitor , angiogenesis inhibitor , calcineurin inhibitor Mylotarg Serious , nonhealing wound , ulcer bone fracture Allergy study medication excipients study medication Investigational drug therapy outside trial within 4 week study entry Any severe concomitant condition make undesirable patient participate study could jeopardise compliance protocol</criteria>
	<gender>All</gender>
	<minimum_age>61 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2015</verification_date>
</DOC>